AGIO Agios Pharmaceuticals Inc.

59.64
+1.05  (2%)
Previous Close 58.59
Open 59.06
Price To book 6.46
Market Cap 2907705796
Shares 48,754,289
Volume 134,292
Short Ratio 14.35
Av. Daily Volume 405,300

SEC filingsSee all SEC filings

  1. 8-K - Current report 171211003
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171167745
  3. 8-K - Current report 171167354
  4. UPLOAD [Cover] - SEC-generated letter
  5. CORRESP [Cover] - Correspondence

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

First data due from expansion trial at ASH December 11, 2017.
Ivosidenib
Frontline Acute myeloid leukemia (AML)
First data due from expansion trial at ASH December 11, 2017.
Ivosidenib
R/R Acute Myeloid Leukemia (AML)
NDA filing due by end of 2017.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 2 first data released at EHA meeting June 2016. Updated data due at EHA June 24, 2017 with further data due at ASH December 10, 2017. Pivotal trials to be initiated 1H 2018.
AG-348
Pyruvate kinase deficiency
Phase 3 initiated 2Q 2017.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of October 2017.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 initiated December 2016.
AG-120
IDH1 mutant positive cholangiocarcinoma - cancer

Latest News

  1. Fighting Cancer One Patient At A Time
  2. Agios Posts New Data on Glioma Candidate from Dose Expansion
  3. Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma
  4. ETFs with exposure to Agios Pharmaceuticals, Inc. : November 16, 2017
  5. Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 9, 2017
  6. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
  7. Today's Research Reports on Stocks to Watch: Exelixis, Inc. and Agios Pharmaceuticals
  8. Edited Transcript of AGIO earnings conference call or presentation 1-Nov-17 12:00pm GMT
  9. Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y
  10. Agios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting
  11. Agios Pharmaceuticals reports 3Q loss
  12. Agios Reports Third Quarter 2017 Financial Results
  13. Agios Pharmaceuticals, Inc. to Host Earnings Call
  14. Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : October 31, 2017
  15. Agios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017
  16. Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : October 30, 2017
  17. Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?
  18. Agios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017
  19. ETFs with exposure to Agios Pharmaceuticals, Inc. : October 23, 2017

SEC Filings

  1. 8-K - Current report 171211003
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171167745
  3. 8-K - Current report 171167354
  4. UPLOAD [Cover] - SEC-generated letter
  5. CORRESP [Cover] - Correspondence
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014141
  7. 8-K - Current report 171013247
  8. UPLOAD [Cover] - SEC-generated letter
  9. 8-K - Current report 17997210
  10. 8-K - Current report 17928885